Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 6032

1.
2.

Elbasvir/grazoprevir in women with hepatitis C virus infection taking oral contraceptives or hormone replacement therapy.

Hézode C, Kwo P, Sperl J, Hwang P, Long J, Talwani R, Robertson MN, Haber BA.

Int J Womens Health. 2019 Nov 20;11:617-628. doi: 10.2147/IJWH.S203022. eCollection 2019.

3.

A once-a-month oral contraceptive.

Kirtane AR, Hua T, Hayward A, Bajpayee A, Wahane A, Lopes A, Bensel T, Ma L, Stanczyk FZ, Brooks S, Gwynne D, Wainer J, Collins J, Tamang SM, Langer R, Traverso G.

Sci Transl Med. 2019 Dec 4;11(521). pii: eaay2602. doi: 10.1126/scitranslmed.aay2602.

PMID:
31801885
4.

Is the injectable contraceptive Depo-medroxyprogesterone acetate (DMPA-IM) associated with an increased risk for HIV acquisition? The jury is still out.

Hapgood H.

AIDS Res Hum Retroviruses. 2019 Dec 4. doi: 10.1089/AID.2019.0228. [Epub ahead of print]

PMID:
31797677
6.

Blood biomarkers for memory: toward early detection of risk for Alzheimer disease, pharmacogenomics, and repurposed drugs.

Niculescu AB, Le-Niculescu H, Roseberry K, Wang S, Hart J, Kaur A, Robertson H, Jones T, Strasburger A, Williams A, Kurian SM, Lamb B, Shekhar A, Lahiri DK, Saykin AJ.

Mol Psychiatry. 2019 Dec 2. doi: 10.1038/s41380-019-0602-2. [Epub ahead of print]

PMID:
31792364
7.

l-glutamine supplementation exerts cardio-renal protection in estrogen-progestin oral contraceptive-treated female rats.

Olaniyi KS, Woru Sabinari I, Olatunji LA.

Environ Toxicol Pharmacol. 2019 Nov 22;74:103305. doi: 10.1016/j.etap.2019.103305. [Epub ahead of print]

PMID:
31790957
8.

Contraceptive Use in Women of Childbearing Ability With Rheumatoid Arthritis.

Ingram E, Claus L, Kolfenbach J, Wright G, Borgelt LM.

J Clin Rheumatol. 2019 Nov 19. doi: 10.1097/RHU.0000000000001184. [Epub ahead of print]

PMID:
31789996
9.

Six-Year Contraceptive Efficacy and Continued Safety of a Levonorgestrel 52mg Intrauterine System.

Westhoff CL, Keder LM, Gangestad A, Teal SB, Olariu AI, Creinin MD.

Contraception. 2019 Nov 28. pii: S0010-7824(19)30444-5. doi: 10.1016/j.contraception.2019.10.010. [Epub ahead of print]

PMID:
31786203
10.

Effect of the levonorgestrel-releasing intrauterine system on cardiovascular risk markers among women with thrombophilia or previous venous thromboembolism.

Braga GC, Brito MB, Ferriani RA, Oliveira LC, Garcia AA, Pintão MC, Vieira CS.

Int J Gynaecol Obstet. 2019 Nov 28. doi: 10.1002/ijgo.13070. [Epub ahead of print]

PMID:
31778208
11.

A randomized controlled pilot study of ulipristal acetate for abnormal bleeding among women using the 52-mg levonorgestrel intrauterine system.

Fava M, Peloggia A, Baccaro LF, Castro S, Carvalho N, Bahamondes L.

Int J Gynaecol Obstet. 2019 Nov 28. doi: 10.1002/ijgo.13068. [Epub ahead of print]

PMID:
31777949
12.
13.

Advanced uterine adenosarcoma with sarcomatous overgrowth in a young woman: A case report.

Wang B, Yang HD, Shi XH, Li H.

Medicine (Baltimore). 2019 Nov;98(47):e18119. doi: 10.1097/MD.0000000000018119.

14.

Emergency Contraception.

Upadhya KK; COMMITTEE ON ADOLESCENCE.

Pediatrics. 2019 Dec;144(6). pii: e20193149. doi: 10.1542/peds.2019-3149. Epub 2019 Nov 18.

PMID:
31740497
15.

Drug release testing of long-acting intrauterine systems.

Bao Q, Zou Y, Wang Y, Kozak D, Choi S, Burgess DJ.

J Control Release. 2019 Nov 13;316:349-358. doi: 10.1016/j.jconrel.2019.11.015. [Epub ahead of print]

PMID:
31733294
16.

Long-acting reversible contraception by effervescent microneedle patch.

Li W, Tang J, Terry RN, Li S, Brunie A, Callahan RL, Noel RK, Rodríguez CA, Schwendeman SP, Prausnitz MR.

Sci Adv. 2019 Nov 6;5(11):eaaw8145. doi: 10.1126/sciadv.aaw8145. eCollection 2019 Nov.

17.

Steroidal contraceptives: effect on carbohydrate metabolism in women without diabetes mellitus.

Lopez LM, Grimes DA, Schulz KF.

Cochrane Database Syst Rev. 2019 Nov 12;2019(11). doi: 10.1002/14651858.CD006133.pub5. Review.

PMID:
31711271
18.

Levonorgestrel IUD: is there a long-lasting effect on return to fertility?

Dinehart E, Lathi RB, Aghajanova L.

J Assist Reprod Genet. 2019 Nov 11. doi: 10.1007/s10815-019-01624-5. [Epub ahead of print] Review.

PMID:
31709489
19.

Differences in continuation rates and early removal between contraceptive and therapeutic use of the levonorgestrel-releasing intrauterine system 52 mg.

Teunissen AM, Merry AHH, Devies IEC, Roumen FJME.

Eur J Contracept Reprod Health Care. 2019 Dec;24(6):449-456. doi: 10.1080/13625187.2019.1682134. Epub 2019 Nov 7.

PMID:
31696740
20.

Clinical Utility Of Elagolix As An Oral Treatment For Women With Uterine Fibroids: A Short Report On The Emerging Efficacy Data.

Neri M, Melis GB, Giancane E, Vallerino V, Pilloni M, Piras B, Loddo A, Paoletti AM, Mais V.

Int J Womens Health. 2019 Oct 22;11:535-546. doi: 10.2147/IJWH.S185023. eCollection 2019. Review.

Supplemental Content

Loading ...
Support Center